Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10438141 | 0.90 | HIF1A (0.58) | HIF1APOLBENPP1P2RY1 | |
| SCHEMBL10438071 | 0.90 | HIF1A (0.58) | HIF1APOLBENPP1P2RY1 | |
| SCHEMBL10438073 | 0.90 | HIF1A (0.58) | HIF1APOLBENPP1P2RY1 | |
| Deoxyinosine SCHEMBL24307 | 0.89 | HIF1A (0.73) | HIF1A | |
| Deoxyinosine SCHEMBL5982293 | 0.89 | HIF1A (0.73) | HIF1A | |
| Deoxyinosine SCHEMBL2000526 | 0.89 | HIF1A (0.73) | HIF1A | |
| Deoxyinosine SCHEMBL7191121 | 0.89 | HIF1A (0.73) | HIF1A | |
| Deoxyinosine SCHEMBL324457 | 0.89 | HIF1A (0.73) | HIF1A | |
| Deoxyinosine SCHEMBL29357821 | 0.89 | HIF1A (0.73) | HIF1A | |
| SCHEMBL9345725 | 0.88 | HIF1A (0.58) | HIF1APOLBENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087465-B2 | Trans-acting elements for intracellular delivery of nucleic acid sequences | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-10-02 | — | — | US | claimed |
| US-20170130246-A1 | TRANS-ACTING ELEMENTS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACID SEQUENCES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-05-11 | — | — | US | claimed |
| WO-2015138868-A9 | TRANS-ACTING ELEMENTS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACID SEQUENCES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-11-19 | — | — | WO | claimed |
| WO-2015138868-A1 | TRANS-ACTING ELEMENTS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACID SEQUENCES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-09-17 | — | — | WO | claimed |
| US-6756496-B1 | SUCH AS TRIETHYLAMMONIUM-5'-DIMETHOXYTRITYL-3'-THYMIDINE-HYDROGEN PHOSPHONONDITHIOATE FOR USE AS ANTIVIRAL AND ANTICANCER AGENTS | ISIS PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | claimed |
| US-6303774-B1 | ANTIVIRAL AGENTS, ANTICANCER AGENTS, METABOLIC MODERATORS | SRI INTERNATIONAL | 2001-10-16 | — | — | US | claimed |
| US-5565555-A | Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues | GILEAD SCIENCES, INC. (US) | 1996-10-15 | — | — | US | claimed |
| US-5194599-A | Forming linkages with nuclosides and nucleotides; viricides, anticarcinogenic agents | GILEAD SCIENCES, INC. (US) | 1993-03-16 | — | — | US | claimed |
| EP-0360609-A2 | Novel hydrogen phosphonodithioate compositions | GILEAD SCIENCES, INC. (US) | 1990-03-28 | — | — | EP | claimed |
| US-10087465-B2 | Trans-acting elements for intracellular delivery of nucleic acid sequences | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170130246-A1 | TRANS-ACTING ELEMENTS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACID SEQUENCES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-05-11 | — | — | US | disclosed |
| WO-2015138868-A9 | TRANS-ACTING ELEMENTS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACID SEQUENCES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015138868-A1 | TRANS-ACTING ELEMENTS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACID SEQUENCES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170130246-A1 | TRANS-ACTING ELEMENTS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACID SEQUENCES | ZYX, TPX2, ZFX | HIF1A 3597/4885POLB 475/4885ENPP1 495/4885 |
| US-10087465-B2 | Trans-acting elements for intracellular delivery of nucleic acid sequences | ZYX, TPX2, ZFX | HIF1A 3597/4885POLB 475/4885ENPP1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.